Publications

Publications for the team Oncostat

Titre Publication Type Publication year Auteur
Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays journalArticle 2018 Jose, V.; Fumagalli, D.; Rothé, F.; Majjaj, S.; Loi, S.; Michiels, S.; Sotiriou, C.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy journalArticle 2018 Ferrara, R.; Mezquita, L.; Texier, M.; Lahmar, J.; Audigier-Valette, C.; Tessonnier, L.; Mazieres, J.; Zalcman, G.; Brosseau, S.; Le Moulec, S.; Leroy, L.; Duchemann, B.; Lefebvre, C.; Veillon, R.; Westeel, V.; Koscielny, S.; Champiat, S.; Ferte, C.; Planchard, D.; Remon, J.; Boucher, M. E.; Gazzah, A.; Adam, J.; Bria, E.; Tortora, G.; Soria, J. C.; Besse, B.; Caramella, C.
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis journalArticle 2018 Bidard, F. C.; Michiels, S.; Riethdorf, S.; Mueller, V.; Esserman, L. J.; Lucci, A.; Naume, B.; Horiguchi, J.; Gisbert-Criado, R.; Sleijfer, S.; Toi, M.; Garcia-Saenz, J. A.; Hartkopf, A.; Generali, D.; Rothé, F.; Smerage, J.; Muinelo-Romay, L.; Stebbing, J.; Viens, P.; Magbanua, M. J. M.; Hall, C. S.; Engebraaten, O.; Takata, D.; Vidal-Martínez, J.; Onstenk, W.; Fujisawa, N.; Diaz-Rubio, E.; Taran, F. A.; Cappelletti, M. R.; Ignatiadis, M.; Proudhon, C.; Wolf, D. M.; Bauldry, J. B.; Borgen, E.; Nagaoka, R.; Carañana, V.; Kraan, J.; Maestro, M.; Brucker, S. Y.; Weber, K.; Reyal, F.; Amara, D.; Karhade, M. G.; Mathiesen, R. R.; Tokiniwa, H.; Llombart-Cussac, A.; Meddis, A.; Blanche, P.; d''''Hollander, K.; Cottu, P.; Park, J. W.; Loibl, S.; Latouche, A.; Pierga, J. Y.; Pantel, K.
High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008 journalArticle 2018 Whelan, J.; Le Deley, M. C.; Dirksen, U.; Le Teuff, G.; Brennan, B.; Gaspar, N.; Hawkins, D. S.; Amler, S.; Bauer, S.; Bielack, S.; Blay, J. Y.; Burdach, S.; Castex, M. P.; Dilloo, D.; Eggert, A.; Gelderblom, H.; Gentet, J. C.; Hartmann, W.; Hassenpflug, W. A.; Hjorth, L.; Jimenez, M.; Klingebiel, T.; Kontny, U.; Kruseova, J.; Ladenstein, R.; Laurence, V.; Lervat, C.; Marec-Berard, P.; Marreaud, S.; Michon, J.; Morland, B.; Paulussen, M.; Ranft, A.; Reichardt, P.; van den Berg, H.; Wheatley, K.; Judson, I.; Lewis, I.; Craft, A.; Juergens, H.; Oberlin, O.
Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death journalArticle 2018 Krol, A.; Tournigand, C.; Michiels, S.; Rondeau, V.
Joint modelling of a binary and a continuous outcome measured at two cycles to determine the optimal dose journalArticle 2018 Ezzalfani, Monia; Burzykowski, Tomasz; Paoletti, Xavier
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
[Proton therapy for head and neck cancers] journalArticle 2017 Blanchard, P.; Frank, S. J.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis journalArticle 2017 Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y.
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice journalArticle 2017 Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial journalArticle 2017 Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L.
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial journalArticle 2017 Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V.
Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study journalArticle 2017 Atlan, P.; Bayar, M. A.; Lanoy, E.; Besse, B.; Planchard, D.; Ramon, J.; Raynard, B.; Antoun, S.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
The frequency of cancer in France: Most recent data and trends journalArticle 2017 Ribassin-Majed, L.; Le-Teuff, G.; Hill, C.
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial journalArticle 2017 Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial journalArticle 2017 Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
In Regard to Arthurs et al journalArticle 2017 Blanchard, P.; Garden, A. S.
Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma journalArticle 2017 Conversano, A.; Mazouni, C.; Thomin, A.; Gaudin, A.; Fournier, M.; Rimareix, F.; Bonastre, J.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial journalArticle 2017 Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium journalArticle 2017 Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study) journalArticle 2017 Fresneau, Brice; Hackshaw, A.; Hawkins, D. S.; Paulussen, M.; Anderson, J. R.; Judson, I.; Litière, S.; Dirksen, U.; Lewis, I.; van den Berg, H.; Gaspar, N.; Gelderblom, H.; Whelan, J.; Boddy, A. V.; Wheatley, K.; Pignon, J. P.; De Vathaire, F.; Le Deley, M. C.; Le Teuff, G.
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort journalArticle 2017 Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A.
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice journalArticle 2017 Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M.
Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? journalArticle 2017 Bossi, A.; Mottet, N.; Blanchard, P.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab journalArticle 2017 Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M.; Vaysse, T.; Marthey, L.; Eggermont, A.; Asvatourian, V.; Lanoy, E.; Mateus, C.; Robert, C.; Carbonnel, F.
Radiation-induced neurocognitive dysfunction in head and neck cancer patients journalArticle 2017 De Felice, F.; Blanchard, P.
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment journalArticle 2017 Annede, P.; Gouy, S.; Mazeron, R.; Bentivegna, E.; Maroun, P.; Petit, C.; Dumas, I.; Leary, A.; Genestie, C.; Lhomme, C.; Deutsch, E.; Morice, P.; Pautier, P.; Haie-Meder, C.; Chargari, C.